Title: Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives
Authors: Vande Casteele, Niels
Feagan, Brian G
Gils, Ann
Vermeire, Severine
Khanna, Reena
Sandborn, William J
Levesque, Barrett G # ×
Issue Date: Apr-2014
Series Title: Current Gastroenterology Reports vol:16 issue:4 pages:378
Article number: 10.1007/s11894-014-0378-0
Abstract: Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel diseases (IBD). Although many patients respond to ant-TNF therapy, a proportion of patients will not respond (primary non-response) or will lose response to the drug over time (secondary non-response). This loss of response can be caused by patient, TNF-inhibitor, or disease-related factors influencing the pharmacokinetics and pharmacodynamics of the drug. Therefore, monitoring pharmacological parameters (i.e. therapeutic drug monitoring) may help guide therapeutic decisions. This review emphasizes interesting and important new findings, and provides an updated overview, on the subject of therapeutic drug monitoring. While exploring the hypothesis that "one size does not fit all", we focused on the first prospective studies investigating the novel approach in IBD of 'target concentration adjusted dosing' and personalized medicine.
ISSN: 1522-8037
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Therapeutic and Diagnostic Antibodies (+)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Vande Casteele 2014_review_self-archived.pdf Published 585KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.